Introduction: Spain was one of the most affected countries during the first wave of COVID-19, having the highest mortality rate in Europe. The aim of this retrospective study is to estimate the impact that remdesivir-the first drug for COVID-19 approved in the EU-would have had in the first wave.
Methods: This study simulated the impact that remdesivir could have had on the Spanish National Health System (SNHS) capacity (bed occupancy) and the number of deaths that could have been prevented, based on two scenarios: a real-life scenario (without remdesivir) and an alternative scenario (with remdesivir). It considered the clinical results of the ACTT-1 trial in hospitalized patients with COVID-19 and pneumonia who required supplemental oxygen. The occupancy rates in general wards and ICUs were estimated in both scenarios.
Results: Remdesivir use could have prevented the admission of 2587 patients (43.75%) in the ICUs. It could have also increased the SNHS capacity in 5656 general wards beds and 1700 ICU beds, showing an increase in the number of beds available of 17.53% (95% CI 3.98%-24.42%) and 23.98% (95% CI 21.33%-28.22%), respectively, at the peak of the occupancy rates. Furthermore, remdesivir use could have prevented 7639 deaths due to COVID-19, which implies a 27.51% reduction (95% CI 14.25%-34.07%).
Conclusions: Remdesivir could have relieved the pressure on the SNHS and could have reduced the death toll, providing a better strategy for the management of COVID-19 during the first wave.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196270 | PMC |
| http://dx.doi.org/10.1007/s12325-021-01804-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID-19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta-Analysis.
Influenza Other Respir Viruses
December 2024
Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, new Territories, Hong Kong SAR, China.
Antiviral drugs likely remain effective against the SARS-CoV-2 Omicron variant, while monoclonal antibody (mAb) therapies have experienced drops in neutralizing ability. This systematic review and network meta-analysis aims to estimate the comparative effectiveness of antivirals and mAb therapies for treating COVID-19 patients infected with Omicron, capturing primarily acute outcomes. We searched multiple databases from July 4 to July 19, 2022, with updates through November 4, 2022.
View Article and Find Full Text PDFSearch interest in alleged COVID-19 treatments over the pandemic period: the impact of mass news media.
medRxiv
November 2024
CompEpi Dispersed Volunteer Research Network, 401 Park Drive, Boston, MA, USA.
Background: Understanding how individuals obtain medical information, especially amid changing guidance, is important for improving outreach and communication strategies. In particular, during a public health emergency, interest in unsafe or illegitimate medications can delay access to appropriate treatments and foster mistrust in the medical system, which can be detrimental at both individual and population levels. It is thus key to understand factors associated with said interest.
View Article and Find Full Text PDFSARS-CoV-2 Resistance to Small Molecule Inhibitors.
Curr Clin Microbiol Rep
September 2024
Department of Chemistry, Delaware State University, Dover, DE 19901, USA.
Article Synopsis
- SARS-CoV-2 mutates over time, leading to new Variants of Concern (VOCs) that can affect how easily the virus spreads, the severity of illness, and how well current antiviral drugs work.
- Recent antiviral drugs like Nirmatrelvir and Ensitrelvir inhibit specific viral proteins (3CLpro), while others like Remdesivir target different proteins (nsp12), but resistance mutations may diminish their effectiveness.
- The review outlines key mutations in these viral proteins and discusses recent advancements in antiviral treatments, highlighting the concern of developing resistance as new variants emerge.
The effects of Remdesivir's functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase.
Antiviral Res
December 2024
Laboratoire Architecture et Fonction des Macromolécules Biologiques (AFMB), CNRS, Aix-Marseille Université, UMR7257, Marseille, France; European Virus Bioinformatics Center, Leutragraben 1, 07743, Jena, Germany. Electronic address:
Remdesivir (RDV, Veklury®) is the first FDA-approved antiviral treatment for COVID-19. It is a nucleotide analogue (NA) carrying a 1'-cyano (1'-CN) group on the ribose and a pseudo-adenine nucleobase whose contributions to the mode of action (MoA) are not clear. Here, we dissect these independent contributions by employing RDV-TP analogues.
View Article and Find Full Text PDFIntranasal liposomal angiotensin-(1-7) administration reduces inflammation and viral load in the lungs during SARS-CoV-2 infection in K18-hACE2 transgenic mice.
Antimicrob Agents Chemother
December 2024
Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
To effectively reduce the health impact of coronavirus disease (COVID-19), it is essential to adopt comprehensive strategies to protect individuals from severe acute respiratory syndrome. In that sense, much effort has been devoted to the discovery and repurposing of effective antiviral and anti-inflammatory molecules. The endogenous peptide angiotensin-(1-7) [Ang-(1-7)] has been recently proposed as a promising anti-inflammatory agent to control respiratory infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!